Tarsus Pharmaceuticals, Inc.
TARS
शेयरों में रैंक
#4606
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
शेयर मूल्य
$70.89
मार्केट कैप
$3.32B
बदलाव (1 दिन)
2.00%
बदलाव (1 वर्ष)
-0.42%
देश
US
व्यापार Tarsus Pharmaceuticals, Inc. (TARS)
श्रेणी
Healthcare
Tarsus Pharmaceuticals, Inc. (TARS) के लिए EPS
June 2026 TTM तक का EPS: $-1.09
Tarsus Pharmaceuticals, Inc. की नवीनतम वित्तीय रिपोर्टों और शेयर मूल्य के अनुसार, कंपनी का वर्तमान EPS (TTM) $-1.09 है। 2023 के अंत में, कंपनी का EPS $-4.62 था, जो 2022 के EPS $-2.52 के की वृद्धि था।
Tarsus Pharmaceuticals, Inc. के लिए 2018 से 2026 तक का EPS इतिहास
प्रत्येक वर्ष के अंत में EPS
| वर्ष | EPS | परिवर्तन |
|---|---|---|
| 2026 (TTM) | $-1.09 | -64.50% |
| 2024 | $-3.07 | -33.55% |
| 2023 | $-4.62 | 83.33% |
| 2022 | $-2.52 | 276.12% |
| 2021 | $-0.67 | -49.24% |
| 2020 | $-1.32 | 450.00% |
| 2019 | $-0.24 | -22.58% |
| 2018 | $-0.31 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए EPS
| कंपनी | EPS | EPS अंतर | देश |
|---|---|---|---|
| $17.32 | -1,688.99% |
US
|
|
| $-7.98 | 632.11% |
US
|
|
| $-5.29 | 385.32% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -2,644.95% |
NL
|
